Cargando…
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial
Autores principales: | Rashidi, Farid, Barco, Stefano, Rezaeifar, Parisa, Sadeghipour, Parham, Ghodrati, Samad, Bakhshandeh, Hooman, Mousavi-Aghdas, Seyed Ali, Sadeghi, Armin, Sharifi, Akbar, Valizadeh, Hamed, Mikaeili, Haleh, Rafiee, Farnaz, Navarbaf, Zahar, Farajian, Gita, Mahmoodpoor, Ata, Bikdeli, Behnood, Ansarin, Khalil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648570/ https://www.ncbi.nlm.nih.gov/pubmed/34969528 http://dx.doi.org/10.1016/j.thromres.2021.12.003 |
Ejemplares similares
-
Cross-cultural validity of the Pulmonary Embolism Quality of Life questionnaire in the quality of life survey after pulmonary embolism: A Persian-speaking cohort
por: Mehdizadeh, Kasra, et al.
Publicado: (2023) -
Clot Burden As a Predictor of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism: A Cohort Study
por: Gharepapagh, Esmaeil, et al.
Publicado: (2023) -
Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals
por: Talasaz, Azita H., et al.
Publicado: (2022) -
Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence
por: Bikdeli, Behnood
Publicado: (2020) -
To escalate thromboprophylacic heparin intensity in COVID‐19 or not? That is still the question
por: Bikdeli, Behnood
Publicado: (2022)